Report of Foreign Issuer (6-k)
August 05 2020 - 1:35PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of August, 2020
Commission
File Number: 001-37353
BIONDVAX
PHARMACEUTICALS LTD.
(Translation
of registrant’s name into English)
Jerusalem
BioPark, 2nd Floor
Hadassah
Ein Kerem Campus
Jerusalem,
Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
BiondVax
Pharmaceuticals Ltd. (hereinafter, the “Registrant”, the “Company”, or “BiondVax”) hereby
furnishes the following documents in connection with its Annual General Meeting of Shareholders scheduled for September 2,
2020 at 4:00 p.m. Israel time at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co., One Azrieli
Center, Tel Aviv 6701101, Israel:
|
|
(1)
|
Notice
and Proxy Statement with respect to the Company’s Annual General Meeting of
Shareholders to be held on September 2, 2020, describing the proposals to be voted
upon at the meeting, the procedure for voting in person or by proxy at the meeting and
various other details related to the meeting; and
|
|
|
(2)
|
Proxy
Card whereby holders of Company shares may vote at the meeting without attending in person.
|
The
Notice and Proxy Statement is furnished with this Form 6-K as Exhibit 99.1 and the Proxy Card is furnished with this Form 6-K
as Exhibit 99.2.
Exhibit
Index
Exhibits
99.1 and 99.2 of this Report on Form 6-K are hereby incorporated by reference into the Company’s Registration Statement
on Form S-8 (Registration No. 333-239344) and its Registration Statement on Form F-3 (Registration No. 333-240189).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
|
|
Date: August 5, 2020
|
By:
|
/s/
Ron Babecoff
|
|
|
|
Ron Babecoff
|
|
|
|
Chief Executive Officer
|
2
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024
